Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00625157|
Recruitment Status : Completed
First Posted : February 28, 2008
Last Update Posted : February 29, 2008
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.
|Condition or disease||Intervention/treatment||Phase|
|Discoid Lupus Erythematosus||Drug: ASF 1096 0.5 % cream Drug: ASF 1096 placebo cream||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study (2)|
Drug: ASF 1096 0.5 % cream
|Placebo Comparator: 2||
Drug: ASF 1096 placebo cream
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00625157
|Roskilde Hospital, Denmark|